United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

Panelists discuss how early detection barriers include nonspecific symptoms like progressive dyspnea that are often misattributed to more common conditions, leading to delayed diagnosis and the need ...

Transplanting gut microbes from healthy rats into a rat model of PAH led to a reduction in disease severity, suggesting a ...

In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, ...

The optimal approach to implementing telemedicine hypertension management in the United States is unknown. Thirteen, 11, and 7 trials were eligible for systolic and diastolic BP difference and BP ...

A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with ...

A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...

Halo Biosciences ("Halo"), a clinical-stage biotechnology company developing extracellular matrix-targeted therapies, today ...

The pulmonary arterial hypertension treatment market has witnessed a significant transformation in recent years, driven by advancements in medical research and increasing awareness about rare ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

A Hundred Experts Urge Strengthening Early Diagnosis of Pulmonary Hypertension in Latin America ...